EU rejection forces blarcamesine back to Phase 3 in Alzheimer's; Rett syndrome and $118M cash keep the story alive pending FDA alignment

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing a targeted neurological drug for Alzheimer's disease that is not yet approved, with an additional program in Rett syndrome also in late-stage testing.

Blarcamesine, a sigma-1 receptor agonist, lost its EU marketing bid for early Alzheimer's disease after CHMP declined and Anavex withdrew the application. The thesis now rests on whether FDA engagement produces an agreed Phase 3 design for AD, while Rett syndrome's RMAT-designated Phase 3 offers a parallel regulatory path. The EU rejection on single-program data, a CEO termination for cause, and Nasdaq filing delinquency compound the structural fragility before any new registrational readout.